T32 Cancer Biology Postdoctoral Training Program

Winship's T32 Cancer Biology Training Program for Postdoctoral Researchers, supported by a grant from the National Cancer Institute, provides enhanced mentored training to postdoctoral trainees researching cancer biology.

Advances in our understanding of the biology of cancer can potentially lead to significant breakthroughs in cancer diagnosis and treatment. But the division in training basic scientists and clinicians has impaired the translation of basic science discoveries into clinical advancements.

This is why there is a compelling need for an enhanced, mentored research training program that will bridge the gap between training in rigorous scientific investigation, following the scientific method, and compassionate clinical care for the patient.

Overview of Program

Winship Cancer Institute of Emory University has received a T32 training grant from the National Cancer Institute to help develop the next generation of researchers and leaders in cancer biology. Eligible postdoctoral trainees (PhD basic scientists and/or MD clinical residents/fellows) will take advantage of Winship's outstanding resources—including our high-caliber investigators and close collaboration between cancer biologists and clinicians—to provide a unique, individualized and multifaceted training experience. The program will support postdoctoral trainees in making transformative discoveries that improve the quality of care for patients by acquiring the knowledge and skills they need to address the most important biological questions and clinically significant problems.

The Winship T32 Training Program in Cancer Biology’s objective is to equip postdoctoral trainees (PhD and/or MD) so they can initiate an impactful, independent research program that will translate novel insights in cancer biology into improvements in clinical care. The program will accomplish its objective by providing trainees with the infrastructure, resources, training, experience and mentorship they need to acquire the depth of knowledge and critical skills in cancer biology research, combined with practical exposure and understanding of clinical concepts.

The training program aims to train the next generation of cancer scientific leaders by providing:

  1. Organized research training;
  2. Comprehensive formal and informal didactics;
  3. Clinical exposure through tumor boards and clinics;
  4. Career development activities; and
  5. Plan for transition to independence.

Selected scholars must be able to commit to full-time laboratory-based research training (40 hours per week as defined by the NIH) for 12-24 months. We expect that scholars will receive salary support and benefits up to $57,300 per year, $4500 in tuition and fees, $1000 for travel, $2500 for childcare costs, and $12,200 in trainee related expenses to support training program initiatives and specific needs for research, which can include supplies, reagents, poster preparation, etc.

The program will combine key didactic, research, and career development components to train independent and productive independent researchers. Scholars will participate in four training components: (1) core competencies, (2) advanced coursework, (3) career development, and (4) mentored research. The mentored research training plan will be supervised by independently funded faculty who will guide the scholar in the development and conduct of his/her research project. All trainees will be required to form a mentoring committee with at least one clinical mentor from the executive committee or research mentors who can provide scientific insight from a clinical perspective.

Eligibility Requirements

Applicants will need to meet the following requirements:

  • Hold a PhD and/or a MD
  • Be a US citizen or permanent resident and otherwise meet all other NIH eligibility criteria
  • Not be participating in another postdoctoral training program
  • Express a strong interest in training in cancer biology research and a commitment to an academic research career as an independent investigator
  • Commit to full-time research training (40 hours per week as defined by the NIH) for 12-24 months. For MD clinical residents/fellows, candidates with prior research training, including a PhD or MS, will be given preferential consideration.

Additional selection criteria along with terms and conditions are outlined in the request for applications.

Excellence through Diversity

To support excellence and diversity among pilot grant applicants and awardees, proposals are encouraged from groups identified as nationally underrepresented in the sciences including women, members of underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds.

Application Process

The application process for the next cycle is open. Applications are due July 28, 2023.

Potential trainees should submit the following:

  • NIH Biosketch (5-page limit, including a personal statement of up to 500 words describing their research interests and commitment to an academic career in cancer biology research)
  • Description of proposed research (up to 500 words)
  • Mentor(s) biosketch, including current funding support (5-page limit)
  • Mentor letter of support (2-page limit)

Applications should be emailed as a single pdf document to Doreen Theune via email no later than 11:59 pm on Friday, July 28, 2023.

Questions about the program should be directed to Program Director David Yu, MD, PhD via email.

Photo of  David Yu, MD, PhD
David Yu, MD, PhD

David Yu, MD, PhD

Jerome Landry MD Chair of Cancer Biology and Professor, Department of Radiation Oncology
Emory University School of Medicine

A radiation oncologist, Dr. Yu specializes in treating head and neck, breast and lung cancers at Loughlin Radiation Oncology Center at Grady.

Photo of  Martha  Arellano , MD
Martha Arellano , MD

Martha Arellano , MD

Associate Director, Division of Hematology, Department of Hematology and Medical Oncology
Emory University School of Medicine

Dr. Arellano is a key member of the patient care team at Winship specializing in treatment of leukemia and myelodysplastic syndromes.

Photo of  Lawrence Boise, PhD
Lawrence Boise, PhD

Lawrence Boise, PhD

Associate Director for Education and Training
Winship Cancer Institute of Emory University

Dr. Boise leads and coordinates research education, training, and mentorship activities at the cancer center as well as cultivates additional cancer-specific educational opportunities across the spectrum of learners.

Photo of  Anita H. Corbett, PhD
Anita H. Corbett, PhD

Anita H. Corbett, PhD

Samuel C. Dobbs Professor, Department of Biology
Emory College of Arts and Sciences

Dr. Corbett's lab study both regulation of nuclear protein import and mRNA processing/export.

Photo of  Jolinta Lin, MD
Jolinta Lin, MD

Jolinta Lin, MD

Associate Professor, Department of Radiation Oncology
Emory University School of Medicine

Dr. Lin practices general radiation oncology and specializes in the treatment of breast and gastrointestinal cancer.

Photo of  Shishir K. Maithel , MD, FACS
Shishir K. Maithel , MD, FACS

Shishir K. Maithel , MD, FACS

Professor, Division of Surgical Oncology, Department of Surgery
Emory University School of Medicine

Dr. Maithel is a board certified surgeon and surgical oncologist with special interest in hepatobiliary malignancies such as liver cancer as well as cancer of the pancreas, stomach, colon, and small intestine.

Photo of  Brent D. Weinberg, MD, PhD
Brent D. Weinberg, MD, PhD

Brent D. Weinberg, MD, PhD

Associate Professor, Department of Radiology and Imaging Sciences
Emory University School of Medicine

Dr. Weinberg's clinical interest is in imaging of the brain and spine, particularly imaging of tumors and degenerative disorders.


Timothy Hua, PhD
Post-doctoral Fellow, Department of Neurosurgery
Emory University School of Medicine
Targeting DNA topoisomerase I for overcoming acquired resistance to third-generation EGFR-TKIs caused by c-MET amplification in non-small cell lung cancer

Jimmy Patel, MD, PhD
Medical Resident, Department of Radiology
Emory University School of Medicine
Radiolabeling and Preclinical PET Evaluation of 18F-labeled brain penetrant PARP1-selective Inhibitors

Frances Bennett, MD
Surgery Resident, Department of Surgery
Emory University School of Medicine
Leveraging CD26 as a Target in T Cells to Treat Patients with Cholangiocarcioma

Cascade Link  TOP